<DOC>
	<DOCNO>NCT02797431</DOCNO>
	<brief_summary>A multicenter , randomize , double-blinded , placebo-controlled study two dose frequency recombinant Interleukin-7 ( CYT107 ) treatment restore absolute lymphocyte count sepsis patient ; IRIS-7A ( Immune Reconstitution Immunosuppressed Sepsis patient ) . A parallel study perform United State America allow common statistical analysis primary end point analysis enrol patient population .</brief_summary>
	<brief_title>Immune Reconstitution Immunosuppressed Sepsis Patients</brief_title>
	<detailed_description>Sepsis lead cause death critically ill patient intensive care unit Europe US . Recently , evidence accumulate sepsis progress state hyper-inflammation state immunosuppression . This immunosuppressive phase characterize increase incidence secondary infection often relatively avirulent opportunistic type pathogen . Currently , new therapeutic approach sepsis occur use immuno-adjuvants boost host immunity . One promise agent Interleukin-7 essential , non-redundant , pluripotent cytokine produce mainly bone marrow thymic stromal cell require T-cell survival.In addition anti-apoptotic property , IL-7 induce potent proliferation naïve memory T-cells potentially support replenishment peripheral T-cell pool severely deplete sepsis . These effect confirm clinical trial National Cancer Institute HIV+ patient . This clinical study test ability IL-7 restore absolute lymphocyte count septic patient markedly reduce level circulate lymphocyte . An effect already confirm preclinical model sepsis .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<criteria>1 . Patients age ≥ 18 yr old &lt; 80 yr 2 . Patients persistent suspect sepsis 48120 hr admission 3 . Two criterion systemic inflammatory response syndrome ( SIRS ) ( see reference # 19 SIRS criterion ) clinically microbiologically suspected infection . 4 . At least one organ failure define SOFA score ≥2 time point 48120 hr admission ICU 5 . Requirement vasopressor treatment follow : ) epinephrine norepinephrine ≥ 0.05 µg/kg/min ideal body weight ; ii ) vasopressin , iii ) dopamine ≥ 45 μg/kg/min ideal body weight , continuously 4 hr , provide least 20 ml/kg ideal body weight crystalloid equivalent volume colloid administer 24hour interval surround start vasopressor treatment , maintain systolic pressure ≥ 90 mmHg mean arterial pressure ≥ 60 mmHg time point sepsis course precede enrollment IL7 study . 6 . Lymphopenia absolute lymphocyte count ≤ 900 cells/mm3 either day consent day prior consent ICU stay . 7 . Predicted length stay ICU two week start drug therapy treatment trial 8 . Ability obtain sign informed consent patient LAR consent . 1 . Cancer current chemotherapy radiotherapy and/or .receipt chemotherapy radiotherapy within last 6 week 2 . Cardiopulmonary resuscitation within previous 4 week without objective evidence full neurologic recovery ) patient minimal chance survival expect live &gt; 35 day define APACHE II score ≥ 35 time consideration study eligibility 3 . Patients history currently evidence autoimmune disease include example : myasthenia gravis , Guillain Barre syndrome , systemic lupus erythematosis , multiple sclerosis , scleroderma , ulcerative colitis , Crohn 's disease , autoimmune hepatitis , Wegener 's etc . 4 . Patients receive solid organ transplant bone marrow transplant 5 . Patients active history acute chronic lymphocytic leukemia 6 . AIDSdefining illness ( category C ) diagnose within last 12 month prior study entry 7 . History splenectomy 8 . Any hematologic disease associate hypersplenism , thalassemia , hereditary spherocytosis , Gaucher 's Disease , autoimmune hemolytic anemia 9 . Pregnant lactate woman 10 . Participation another investigational interventional study within last 6 month prior study entry , exception study aim test sedation product belong standard care Propofol , Dexmedetomidine , Midazolam . 11 . Patients receive immunosuppressive drug , e.g. , TNFalpha inhibitor , rheumatoid arthritis , inflammatory bowel disease reason , systemic corticosteroid hydrocortisone dose 300 mg/day 12 . Patients receive concurrent immunotherapy biologic agent include : growth factor , cytokine interleukin , ( study medication ) ; example IL2 , growth factor , interferon , HIV vaccine , immunosuppressive drug , hydroxyurea , immunoglobulin , adoptive cell therapy 13 . Prisoners</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>